Key Highlights

  • BillionToOne shares closed down 39% at $91.65.
  • Q2 revenue reached $109.45 million, up 64% year-over-year.
  • Oncology testing revenue surged 176% to $13.7 million.
  • The company reaffirmed full-year 2026 revenue guidance of $450 million to $465 million.

BillionToOne, Inc. (NASDAQ: BLLN) shares closed down 39% at $91.65 despite the company disclosing second-quarter revenue of $109.45 million, representing a robust 64% year-over-year increase fueled by a 35% rise in test volume and a 21% improvement in average selling price to $551.

What Happened

The company achieved net income of $0.15 per share, meeting analyst consensus, while oncology testing revenue surged 176% to $13.7 million, with gross margins reaching 70% and positive operating income of $5.5 million.

Market Reaction

Shares fell sharply despite the strong growth metrics and reaffirmed guidance, a decline that stands in contrast to the generally constructive underlying results, including test volume growth, pricing improvement, and profitability.

Outlook

Management reaffirmed its full-year 2026 revenue outlook of $450 million to $465 million; the disclosed information does not specify a reason for today's decline despite this reaffirmed guidance and the quarter's strong results.

Why did BillionToOne shares fall 39% despite strong Q2 results?

The disclosed information does not specify a reason for the decline beyond the reported results and reaffirmed guidance.

How much did BillionToOne's oncology testing revenue grow?

176% to $13.7 million.

What is BillionToOne's full-year 2026 revenue guidance?

$450 million to $465 million, reaffirmed with the Q2 report.